Document is current

Article History

Accepted: 9 August 2024

First Online: 30 September 2024

Competing interests

: A.J.M. has served as an adviser/consultant for AstraZeneca, Guardant Health, Illumina, Myriad Genetics, Natera, SAGA Diagnostics and Science for America. A.J.M.’s research is supported by a National Institutes of Health K12 grant (K12CA087723). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. A.R. holds equity in Roche. N.W. is an employee of Genentech/Roche and has equity in Roche, Relay Therapeutics and Flare Therapeutics. L.G. is an employee of Genentech/Roche and has equity in Roche. A.P. has held Equity in C2i Genomics, XGenomes, Cadex, Vionix and Parithera. In the past 36 months, she has served as an adviser/consultant for Eli Lilly, Mirati, Pfizer, Inivata, Biofidelity, Checkmate Pharmaceuticals, FMI, Guardant, Abbvie, Bayer, Delcath, Taiho, CVS, Value Analytics Lab, Seagen, Saga, AZ, Scare Inc., Illumina, Taiho, Hookipa, Kahar Medical, Xilio Therapeutics, Sirtex, Takeda and Science for America. She receives fees from Up to Date. She has received travel fees from Karkinos Healthcare. She has been on the DSMC for a Roche study and on the Steering Committee for Exilixis. She has received research funding to the Institution from PureTech, PMV Pharmaceuticals, Plexxicon, Takeda, BMS, Mirati, Novartis, Erasca, Genentech, Daiichi Sankyo, Syndax, Revolution Medicine and Parthenon. A.P.’s research is supported by an NIH/NCI K08 grant (K08273688). A.B.C. and E.S.L. declare no competing interests.